WARNING:
Major Prostate Biopsy Billing Changes Ahead
We’re just weeks away from your prostate biopsy revenue coming to a hard stop.
The AMA has formally announced that CPT® code 55700, the long-standing standard for prostate biopsy reimbursement, will be deleted effective January 1, 2026, as part of the May 2024 CPT Editorial Panel updates.
It’s being replaced with nine new codes favoring advanced technologies, including MRI-targeted fusion biopsy systems like Navigo 4D. Without these technologies in place, your practice could face billing disruptions, compliance violations, and revenue loss.
Don’t wait until January to act. Book a consultation today to prepare your team, protect your bottom line, and stay ahead of revenue disruptions in 2026.
Put Your Reimbursement Plan Into Action Before Jan 1
Act Now or Face Reimbursement Chaos on January 1
The deletion of CPT 55700 is more than just a billing update. It’s a complete shift in how prostate biopsies are performed and reimbursed.
Practices that don’t act now risk:
Billing denials and reimbursement delays
Compliance challenges under new CPT standards
Billing denials and reimbursement delays
UC-Care is helping practices prepare early and stay profitable with a risk-free adoption offer available for a limited time.
With no long-term commitments, our team will guide your practice through every step—aligning your clinical, operational, and billing workflows with the new MRI-targeted fusion biopsy standards.
Protect Revenue by Adopting the Navigo 4D Fusion Navigation System
With low upfront costs, flexible payment options, and the ability to improve efficiency and diagnostic accuracy, Navigo 4D Fusion Navigation System has long been a powerful growth strategy for urology practices.
But now, it’s more than a growth driver—it’s a requirement for compliance and revenue stability under the new CPT codes.
Urology practices that adopt MRI-targeted fusion biopsy with Navigo 4D are gaining a clear clinical and financial edge—before it’s too late.
Unmatched Accuracy
Real-time MRI-US fusion creates a 3D view of the prostate, improving detection of high-grade cancers and enabling earlier, more precise treatment decisions.
Future-Proof Your Billing
Align with the 2026 CPT updates now to avoid denials, delays, and revenue loss—while ensuring smooth, compliant billing from day one.
Lead the Market, Don’t Chase It
Early adopters will be trained, fully integrated, and ready for unimpeded reimbursements before competing practices even begin the transition.
Profit Without the Risk
UC-Care’s pay-per-procedure model makes adoption affordable, with no long-term commitment. Most practices see full ROI within the first year, thanks to higher reimbursements, improved efficiency, and quicker procedures.
The 2026 CPT shift is coming fast. Act now to stay compliant, profitable, and ahead of the competition.
What Practices Are Saying
The Navigo 4D Fusion Navigation System aligns with the new CPT codes and meets all compliance requirements that go live on January 1, 2026—meaning simpler reimbursement and less financial risk for your practice, without the cost barriers that come with other fusion biopsy systems.
But don’t just take our word for it—see what practices already using Navigo are saying!
A UC-Care specialist will reach out within one business day to discuss your goals and guide you through the next steps toward compliance and profitability.